ARK Investment Management LLC Has $42.61 Million Position in Schrödinger, Inc. (NASDAQ:SDGR)

ARK Investment Management LLC decreased its stake in shares of Schrödinger, Inc. (NASDAQ:SDGR - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,208,758 shares of the company's stock after selling 127,710 shares during the period. ARK Investment Management LLC owned approximately 3.03% of Schrödinger worth $42,607,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Paradigm Asset Management Co. LLC acquired a new position in Schrödinger during the 4th quarter valued at about $50,000. Handelsbanken Fonder AB increased its stake in Schrödinger by 19.2% during the 4th quarter. Handelsbanken Fonder AB now owns 14,300 shares of the company's stock valued at $276,000 after buying an additional 2,300 shares during the period. Principal Financial Group Inc. increased its stake in Schrödinger by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 270,449 shares of the company's stock valued at $5,217,000 after buying an additional 8,138 shares during the period. Stephens Investment Management Group LLC increased its stake in Schrödinger by 4.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,607,656 shares of the company's stock valued at $31,012,000 after buying an additional 67,786 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Schrödinger by 60.2% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company's stock valued at $67,718,000 after buying an additional 1,319,464 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Piper Sandler lowered their price objective on shares of Schrödinger from $50.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday. KeyCorp lifted their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, BMO Capital Markets lifted their price objective on shares of Schrödinger from $25.00 to $28.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.50.

Schrödinger Stock Up 0.3 %

Shares of Schrödinger stock traded up $0.06 during trading on Friday, hitting $22.31. The stock had a trading volume of 1,071,695 shares, compared to its average volume of 1,027,856. The stock has a 50 day simple moving average of $22.34 and a 200 day simple moving average of $20.59. The company has a market capitalization of $1.63 billion, a PE ratio of -9.53 and a beta of 1.61. Schrödinger, Inc. has a 1 year low of $16.67 and a 1 year high of $29.15.

Schrödinger (NASDAQ:SDGR - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The firm had revenue of $88.32 million during the quarter, compared to analysts' expectations of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. As a group, equities analysts expect that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.